Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$4.22
-0.09 (-2.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-119.7M · quality 75.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.2%
↓Gross Margin
43.7%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.7%
FCF CAGR
—
FCF margin
-42.0%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $322.5M · net income $-193.2M · FCF $-135.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $322.5M | $322.5M | $379.8M | $196.8M | $289.3M |
| Net Income | $-193.2M | $-193.2M | $-130.8M | $-151.5M | $-195.9M |
| EBITDA | $-139.4M | $-139.4M | $-64.0M | $-100.9M | $-137.7M |
| EPS | -0.27 | -0.27 | -0.18 | -0.21 | -0.27 |
| Gross Margin | 43.7% | 43.7% | 46.9% | 46.7% | 67.8% |
| Operating Margin | -28.9% | -28.9% | -17.7% | -59.1% | -57.5% |
| Net Margin | -59.9% | -59.9% | -34.4% | -77.0% | -67.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.34 | 0.61 | 0.55 |
| Current Ratio | 1.15 | 1.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-135.5M | $-135.5M | $-119.7M | $-61.0M | $-109.2M |
| Returns | |||||
| ROE | -31.2% | -31.2% | -17.0% | -16.3% | -17.3% |
| Valuation | |||||
| P/B | 4.87 | 4.87 | 4.72 | 4.42 | 3.82 |
| Growth & Yield | |||||
| Revenue Growth | -15.1% | -15.1% | 92.9% | -32.0% | — |
| EPS Growth | -50.0% | -50.0% | 14.3% | 22.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.18 → -0.27
Residual
-14.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.